Might want to get in this one now...FDA decision here on Thelin on April 15/18 sometime around then. I bet it gets FDA approved this time, which will be huge! Bargain prices here.
Posted by netguy81 on :
thanks for the post ... if this thing any any kind of run like DNDN .. that would be great !!
Posted by stocktrader22 on :
taking off $3.40 now.
Posted by Bluemound_Freak on :
got in at 3.34, now lets see what happens.
Posted by scottfest on :
Been watching this. You think there is a dip coming st22 or do I need to jump in now.
Posted by stocktrader22 on :
scottfest..hard to tell...been up a lot the past few days, but FDA approval may be right around the corner. I got in at $3.24 and $3.25 this morning. With FDA approval this doubles or more..but I think this runs well until FDA decision.
Posted by scottfest on :
Screw it I'm in. Even if it does dip down a little, the payoff should be greater in the end.
Posted by netguy81 on :
$3.57 now ... Posted by stocktrader22 on :
Yup, shorts are scared big time! You'd think Thelin gets approved this time. Especially since European Union its already been approved in.
Posted by netguy81 on :
here is the link to the PR regarding EU approval and starting marketing in Ireland
it's climbing and climbing..
Posted by stocktrader22 on :
Yup...this is the momo player of the week...looking for $4 tomorrow.
Posted by Livinonklendathu on :
I thought the date was June 15th, got a link showing otherwise?
HOUSTON, Dec. 28, 2006 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals (Nasdaq:ENCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's complete response to the July 24, 2006 approvable letter regarding its New Drug Application (NDA) for THELIN(tm) (sitaxsentan sodium) 100 mg tablets. The FDA has designated the review as a Class 2 resubmission and issued a new Prescription Drug User Fee Act (PDUFA) target action date of June 15, 2007.
Posted by stocktrader22 on :
My mistake, bad rumor going around about fda panel vote on that date, which I do not believe is true. Regardless with the tremendous pipeline this company has, it is obvious its undervalued.
Thelin is a billion dollar drug, and tcb-3711 is even better!
Posted by T e x on :
Am not versed in these (although I posted one tonight), but if you follow these plays, isn't it fairly easy to guage dates for rulings/hearings/events, etc?
Posted by stocktrader22 on :
quote:Originally posted by T e x: Am not versed in these (although I posted one tonight), but if you follow these plays, isn't it fairly easy to guage dates for rulings/hearings/events, etc?
Yes it normally is, but sometimes not as easy as you think. FDA runs on a weird schedule, not to mention since managing my dad's IRA account, bio-firms have become new to me. But thats why ive posted so many lately, risk vs reward with the ones that trade near cash value are tremendous.
Posted by T e x on :
lol, understood...nothing's easy...
Posted by stocktrader22 on :
quote:Originally posted by T e x: lol, understood...nothing's easy...
Have you seen what they have in their pipeline? Some of these are blockbuster drugs with FDA approval.
Posted by T e x on :
no...
I simply picked up on CORT, cuz of PR, then background check: insider filings...
was simply making sure these "announcements" are somewhat routine...
Posted by a surfer on :
3.90 up almost 10% pre-market.
Posted by stocktrader22 on :
i'll probably take the money and run..
Posted by stocktrader22 on :
All out at $3.83 from $3.25
NICE
Posted by RagingBull on :
thought u was looking for 4, pumper lol
Posted by stocktrader22 on :
Was looking for 4 buddy, but I saw the market sentiment this morning, and sometimes you just want to take the profit. I'm quite the pumper lol when >50% of my picks are winners lol
Posted by SherriT on :
Congrats!
Posted by Livinonklendathu on :
quote:Originally posted by stocktrader22: My mistake, bad rumor going around about fda panel vote on that date, which I do not believe is true. Regardless with the tremendous pipeline this company has, it is obvious its undervalued.
Thelin is a billion dollar drug, and tcb-3711 is even better!
No prob, I know where the rumor came from, pretty obvious.
Posted by RagingBull on :
nice ... next week should be interesting !!
Posted by stocktrader22 on :
This thing looks extremely strong, i pulled out my money, but will re-enter when it gets closer to FDA approval if price is justified.
Posted by stocktrader22 on :
Looks like next week it will continue its increase...but profit is profit!
Posted by netguy81 on :
profit is always good ... nothing wrong with that !!
Posted by Livinonklendathu on :
to bad there wasnt that fda decision anymore than it may have turned out like DNDN, it would have been nice
Posted by scottfest on :
HOUSTON, April 16, 2007 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals (ENCY) today announced the commercial availability of THELIN(r)(1) (sitaxentan sodium(2)) 100 mg tablets in the Netherlands for the treatment of pulmonary arterial hypertension (PAH). The Company received European Union marketing authorization for THELIN from the European Commission in August 2006. THELIN is the first selective endothelin A receptor antagonist and the first once-daily oral treatment available for patients with PAH.
THELIN is indicated for improving exercise capacity in PAH patients classified as World Health Organization (WHO) functional class III. Efficacy has been shown in primary pulmonary hypertension(3) and pulmonary hypertension associated with connective tissue disease (CTD).
"As a once-daily oral therapy, THELIN may provide PAH patients with effective symptom management in a convenient, non-invasive route of administration," said Anco Boonstra, M.D., Ph.D., pulmonologist, Vrije Universiteit Medical Center, Amsterdam. "THELIN is a welcome new treatment option for patients with primary disease and also those with CTD-related PAH, where THELIN has demonstrated a therapeutic benefit."
The European Commission's centralized licensing procedure permits Encysive to market THELIN in all 27 member states of the European Union. THELIN has been launched in three member states to date, and will be commercialized in successive EU countries as local government approval for reimbursement is obtained.
- Nice movement this morning.
Posted by scottfest on :
Still moving 3.78!
Posted by scottfest on :
Up 7% today. Hopefully the begining of an upward trend.
Posted by scottfest on :
May 7, 2007 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals (ENCY) today announced financial results for the first quarter ended March 31, 2007.
"In the quarter, we made significant progress advancing our regulatory and product commercialization plans," said Bruce D. Given, M.D., President and CEO of Encysive Pharmaceuticals. "While we continue to make sales and reimbursement inroads in the U.K. and Germany, we have just begun the process of commercializing Thelin(r)(1) in the Republic of Ireland and The Netherlands, and we expect to begin marketing Thelin in additional European countries later in the year. Also in the quarter, we achieved regulatory approval for Thelin in Australia and look to decisions concerning Thelin(tm) from both the U.S. FDA and Canada in the coming months."
First Quarter 2007 Financial Overview
-- Revenues of $5.4 million for the first quarter of 2007, compared to $3.6 million for the first quarter of 2006, reflected approximately $1.0 million in Thelin European sales and a year- over-year increase in Argatroban royalty income of approximately $0.9 million. -- For the first quarter of 2007, the Company reported a net loss of $29.9 million, or $0.49 per basic and diluted share, compared to a net loss of $30.0 million, or $0.51 per basic and diluted share, for the same period last year. -- Research and development spending for the first quarter of 2007 of $17.5 million, was slightly lower than last year's R&D spending in the first quarter of $18.4 million, due to a slowdown in clinical spending. -- Sales and marketing expenses were $10.9 million for the current quarter as compared to $9.8 million for the first quarter in 2006. General and administrative expenses were $5.6 million for the first quarter of 2007, as compared to $5.7 million during the same period in 2006. These changes reflect decreased spending in the U.S. due to internal spending controls, offset by increased spending in Europe where we are actively commercializing Thelin(r). -- Cash, cash equivalents, accrued interest and restricted cash at March 31, 2007 was $62.9 million, compared to $43.8 million at December 31, 2006. Cash utilization during the first quarter included $4.5 million in debt repayment related to the Argatroban Notes (as defined below), as well as $1.6 million in interest payments to the 2005 Convertible Note holders. The March 31 cash balance does include $10.2 million of restricted cash, related to the Argatroban Notes, held in a holdback account, pending resolution of a United Kingdom tax withholding issue. Q1 and Recent Company Highlights
-- In February 2007, Encysive's newly formed wholly-owned subsidiary, Argatroban Royalty Sub LLC (Royalty Sub), placed $60 million in aggregate principal amount of non-convertible notes (Argatroban Notes) in a private placement to institutional investors. The Argatroban Notes are secured by royalties to be paid to Royalty Sub from sales of Argatroban by GlaxoSmithKline (GSK) and by a pledge by Encysive of the stock of Royalty Sub. Going forward, Encysive will continue to report Argatroban royalty income received from GSK in our quarterly financial results. However, the Argatroban royalty income will now be used to repay the Argatroban Notes, and will no longer be available to support the operational cash requirements of the Company. -- In October 2006, Encysive entered into a common stock equity financing line with Azimuth Opportunity Ltd pursuant to which Encysive may sell to Azimuth up to $75 million of common stock or 11,866,851 shares of common stock, whichever comes first. During the 18-month term of the equity line, Encysive may sell, at its sole discretion, registered shares of its common stock to Azimuth at a predetermined discount to the market price, subject to certain limitations. During the first four months of 2007, Encysive made two draw downs, for total gross proceeds of $18 million. Since entering into the Azimuth agreement, Encysive has made a total of four draw downs, for total gross proceeds of $36 million. Of the 11,866,851 shares of common stock originally available under the Azimuth equity financing line, 2,840,755 shares remain available for future draw downs. Encysive intends to use the net proceeds of this equity line for general corporate purposes, including the development and commercialization of the Company's products. -- In March 2007, the Australian Therapeutics Goods Administration (TGA) granted marketing approval for Thelin (sitaxentan sodium) 100 mg tablets for patients with pulmonary arterial hypertension (PAH). The Company is now seeking reimbursement approval in Australia. -- Also in March, the Company re-initiated a Phase II dose ranging study of TBC3711, Encysive's next-generation, highly selective endothelin A antagonist. The 12-week, multi-center, randomized, double-blind, placebo-controlled study will evaluate four once- daily oral doses of TBC3711 in approximately 150 patients diagnosed with resistant hypertension. -- Encysive announced the commercial availability of Thelin(r) for PAH in the Republic of Ireland and in The Netherlands in April 2007. The European Commission's centralized licensing procedure permits Encysive to market Thelin in all 27 member states of the European Union. Thelin will be commercialized in other European countries as local government reimbursement approvals are obtained. Upcoming Presentations and Events
-- May 15 Rodman & Renshaw 4th Annual Global Healthcare Conference, Monte Carlo, Monaco* -- May 19-24 American Thoracic Society (ATS) International Conference, San Diego -- June 13-16 European League Against Rheumatism (EULAR), Barcelona, Spain -- June 15 U.S. FDA Prescription Drug User Fee Act (PDUFA) Date for Thelin NDA
Posted by scottfest on :
Up almost 5% on no news, nice. Patience will pay on this one.
Posted by Mortimer on :
My patience will run out in 26 days, unless the FDA has something REALLY good to say.
I don't mind days like this though Posted by stocktrader22 on :
LOL...yeah ive been in this since $3.49 bought a little high...but anyways holding for the big winner here...FDA approval brings this to $10+ IMO
Posted by stocktrader22 on :
Who wants to play a guessing game on how high it goes before approval date on anticipation?
Thelin is a blockbuster drug,
TH3711- a blood pressure drug will be another one if it can continue to progress.
Posted by scottfest on :
Holding yesterday's gain and adding to it today.
Posted by Mortimer on :
quote:Originally posted by stocktrader22: Who wants to play a guessing game on how high it goes before approval date on anticipation?
Well, I'm hoping for high 5's on anticipation. I would like to play the "approval/rejection" period with free shares only. I felt certain it would get approved the last time around, which if I recall correctly was it's 3rd time around. The drug now has good market share in Europe so maybe this accounts for something to the FDA. Also, apparently there is this other company Gilead (Nas: GILD) has a PAH drug as well up for FDA approval 3days after ENCY's.
What's up with this? Don't get me wrong I love the gains, but I can't find any news or any dates on approval. I am wondering if I should buy more now or wait for a dip, if there is one.
Posted by SherriT on :
Probably just anticipation of approval, given that it is being used in EU now. I went ahead and bought a few....GLTA
(Edit: Thanks for the thread, ST22!)
Posted by stocktrader22 on :
quote:Originally posted by scottfest: What's up with this? Don't get me wrong I love the gains, but I can't find any news or any dates on approval. I am wondering if I should buy more now or wait for a dip, if there is one.
lol buddy...
its the yearly anticipation for this one on FDA approval June 15th....with approval this thing could really take off. Thelin is a migraine drug with a multibillion market...but they have to get approved first lol
Posted by Bluemound_Freak on :
I have shares of ENCY that I bought at 3.38, I can only imagine how happy I could be if this gets an approval on the 15th!
Posted by stocktrader22 on :
If possible try to protect all your capital before the date, if price goes up high enough in anticipation, then hold some for the huge winner. Personally, I may just risk it and leave it all hoping for approval. Worse case IMO is it drops to $1.75-$2.00 and then I gotta hold on for a while waiting for their next blockbuster drug TH3711 to be strung along.
Posted by Bluemound_Freak on :
I have less than 5 K invested in this...........Might as well put it into a slot machine cause I too am holding for the big winnah winnah chicken dinnah!
I thought about cashing out when it hits 4.5-5.0 but how bad would I hate myself when it hits 2.00..........Not near as bad as I would when it hits 10.00 and I am holding half as much!
With the pipeline that they have......I will hold! Posted by SherriT on :
Anyone have any idea what the percentage is of drugs used overseas compared to those that are approved state-side?
Posted by stocktrader22 on :
No not sure, the only concerning thing in this one is no one knows for sure the effect on the stock price and sales of the competing drug by Gilead, there are analysts saying Gilead drug will get approval and its better then Thelin, others saying the opposite. Some analysts say ENCY should be at $3 even with approval, some analysts saying with approval this is a $15-$20 stock.
Posted by SherriT on :
I suspect as long as Thelin gets approved, we will see a nice spike...then, after seeing if Gilead drug gets approved three days later, we may see another dramatic change up or down.
Anyone with a migraine would likely try both drugs at some point, so I don't care much about which is "better" at this point.
Posted by Mortimer on :
$4 million is very small compared to a billion. There surely is room for both drugs to be approved and both make their companies a lot of revenue even if there are already FDA approved PAH drugs in the space. Copy-n-pasted from two seperate articles:
"The overall market for these drugs is expected to expand to about $1 billion annually, with the introduction of ambrisentan and Thelin."
and
"...one plus for Encysive is that it received approval to market Thelin in Europe last year and has already captured a 40% market share in the region. While sales of the drug – at $1 million in the first quarter – were lower than expected, the capture of the market share is not insignificant".
Posted by RagingBull on :
quote:Originally posted by stocktrader22: No not sure, the only concerning thing in this one is no one knows for sure the effect on the stock price and sales of the competing drug by Gilead, there are analysts saying Gilead drug will get approval and its better then Thelin, others saying the opposite. Some analysts say ENCY should be at $3 even with approval, some analysts saying with approval this is a $15-$20 stock.
alnalysts thats what made me jump into this field funny how they're always at the complete opposite side of the spectrum ,one says red the other says blue so i say yellow that makes me an expert also lol
Posted by SherriT on :
LOL Analyst - Weather Person in the South.
Posted by Mortimer on :
There seems to be some resistance at 3.75 It would be nice to break through sometime soon.
Posted by SherriT on :
Yep - would be nice. I would love to see above $4 the first week of June in anticipation.
Posted by stocktrader22 on :
Here we go people!! Hold on tight and don't fall off!!!
Posted by Bluemound_Freak on :
been holding this patiently for about 2 months! now it is finally getting some LOVE! Posted by Livinonklendathu on :
Settled in the 4.50 - 4.55 area, tomorrow should be fun.
Posted by SherriT on :
Gotta love Canadian approval! Tomorrow should be very nice on this one! Hopefully we get a nice gapper.....
Posted by scottfest on :
I'm ready.
Posted by stocktrader2006 on :
Canadian approval?
I thought ENCY was waiting for US FDA approval?
Posted by scottfest on :
quote:Originally posted by stocktrader2006: Canadian approval?
I thought ENCY was waiting for US FDA approval?
We are, but gaining momentum with Canadian approval.
Posted by SherriT on :
quote:Originally posted by scottfest:
quote:Originally posted by stocktrader2006: Canadian approval?
I thought ENCY was waiting for US FDA approval?
We are, but gaining momentum with Canadian approval.
Yep. The fact that it is approved in both Europe and now Canada gives me a little more confidence that the US may approve in a couple of weeks.
Posted by ityab0y on :
wooo i own this!.
june 15th baby!
Posted by blou on :
Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Arterial Hypertension First Selective Endothelin A Receptor Antagonist, First Once-Daily Oral Treatment
Last Update: 5:46 PM ET May 30, 2007
HOUSTON, May 30, 2007 (*********wire via COMTEX) -- Encysive Pharmaceuticals (ENCY : encysive pharmaceuticals inc com Last: 4.12+0.53+14.76% 9:51am 05/31/2007 ENCY4.12, +0.53, +14.8%) today announced that Health Canada's Therapeutic Products Directorate has approved THELIN(tm) (sitaxsentan sodium) 100 mg tablets. THELIN is indicated for the treatment of primary pulmonary arterial hypertension (PAH) and pulmonary hypertension secondary to connective tissue disease, in patients with World Health Organization (WHO) functional class III who have not responded to conventional therapy. THELIN is also indicated in patients with WHO functional class II who did not respond to conventional therapy and for whom no appropriate alternative can be identified. THELIN is the first selective endothelin A receptor antagonist (ETRA) available, and the only once-daily oral treatment approved for PAH. PAH is estimated to afflict approximately 100,000 to 200,000 people in North America and Europe. The disease is characterized by high blood pressure and structural changes in the walls of the pulmonary arteries, the blood vessels that connect the right side of the heart to the lungs. As these arteries become increasingly constricted, blood flow and oxygenation may be inadequate to meet the body's demands. The heart must then pump harder to overcome the resistance, and patients become susceptible to heart failure. "The approval of THELIN represents an advance in the treatment options available for PAH patients in Canada," commented David Langleben, M.D., Professor of Medicine, McGill University and Director of the Center for Pulmonary Vascular Disease, Jewish General Hospital, Montreal. "THELIN's safety and efficacy profile and once-a-day oral formulation make it an attractive therapeutic option, and I look forward to its commercial availability." "THELIN has demonstrated a unique benefit for individuals who have developed PAH as a result of a connective tissue disease, such as scleroderma," said Janet Pope, M.D., Professor of Rheumatology, University of Western Ontario and Director, Division of Rheumatology, St. Joseph's Health Centre, London, Ontario. "As a clinician, I welcome any new treatment that may help these particular patients, as they are a more difficult group to treat." THELIN's approval is based on the largest database of patients with PAH ever assembled in an original Canadian New Drug Submission, with more than 1,000 PAH patients receiving THELIN. Encysive received European Union marketing authorization for THELIN in August 2006, marketing approval from the Australian Therapeutic Goods Administration in March 2007 and the drug is currently under evaluation by the Food and Drug Administration (FDA) in the United States. "This approval is another important step in our effort to commercialize THELIN worldwide," stated Bruce D. Given, M.D., President and Chief Executive Officer of Encysive Pharmaceuticals. "We're extremely proud to have achieved this milestone and look forward to bringing THELIN to PAH patients in Canada." THELIN(tm) (Sitaxsentan Sodium) Canadian Marketing Authorization Highlights The Canadian market authorization was based on submitted data from quality (chemistry and manufacturing) studies, as well as data from non-clinical and clinical studies. Two randomized, double-blind, multi-centre, placebo-controlled studies (n=425) were conducted to demonstrate efficacy and safety. Compared to placebo, treatment with THELIN resulted in a significant increase in exercise capacity. The placebo-corrected increases in six-minute walk distance compared to baseline were 35 meters and 31 meters for the two pivotal studies. Compared to placebo-treatment, THELIN demonstrated improvements to the cardiac index, pulmonary vascular resistance, and systemic vascular resistance after 12 weeks of treatment. Compared to placebo-treatment, THELIN improved functional class. A significant reduction in the rate of clinical worsening was also reported in patients treated with THELIN. In the STRIDE program, THELIN 100 mg was shown to significantly improve exercise capacity, as measured by improvement in six-minute walk distance, including in patients with connective tissue disease. THELIN was also shown to reduce patients' PAH symptoms (improvement in WHO/NYHA functional class) and improve PAH hemodynamic status. Survival of patients was 96% at one year in the overall patient population and 98% in patients with PAH secondary to connective tissue disease. Important Safety Information Like other ETRAs, THELIN is teratogenic, and pregnancy must be excluded before the start of treatment and prevented thereafter by the use of a reliable method. Monthly pregnancy tests during treatment with THELIN are recommended. THELIN has a potential for liver toxicity. Testing of liver enzymes is required prior to the initiation of THELIN and monthly thereafter. In placebo-controlled clinical trials, the most commonly reported adverse events with THELIN treatment were headache, peripheral edema, nasal congestion, nausea, constipation, epistaxis, insomnia, prothrombin time prolonged and international normalized ratio (INR) increase. Because THELIN inhibits the metabolism of warfarin, a dose adjustment is needed when co-administered with THELIN. THELIN is contraindicated in patients receiving cyclosporine A, patients with mild to severe hepatic impairment (Child-Pugh Class A-C), patients with elevated liver aminotransferases prior to starting treatment (elevation in liver enzymes to levels greater than 3 times the upper limit of normal), lactating patients, or patients with hypersensitivity to the active substance or any excipients. THELIN(tm) (Sitaxsentan Sodium) Overview THELIN is an endothelin A receptor antagonist, a small molecule that blocks the action of endothelin, a potent mediator of blood vessel constriction and growth of smooth muscle in vascular walls. Endothelin receptor antagonists may prove to be effective in the treatment of a variety of diseases where the regulation of vascular constriction is important. THELIN is 6,500-fold selective in the targeting of the endothelin A receptor versus the endothelin B receptor. Selective endothelin A receptor antagonism has been shown to increase blood flow and reverse vasoconstriction in human clinical pharmacology studies.
Posted by scottfest on :
Lovin' these gains.
Posted by SherriT on :
Heavy volume during lunch, and a PPS rising to boot....something coming?
Posted by SherriT on :
Over 4.50 now.....25 in a short time....
Posted by scottfest on :
quote:Originally posted by SherriT: Over 4.50 now.....25 in a short time....
Are you saying this thing hits $25? If so, are you thinking this year?
Posted by SherriT on :
quote:Originally posted by scottfest:
quote:Originally posted by SherriT: Over 4.50 now.....25 in a short time....
Are you saying this thing hits $25? If so, are you thinking this year?
WHOA - no, not at all....I was saying .25 cents had been added in a short period of time. Guess I should have added a space in between my ...
Sorry!
Posted by RagingBull on :
lol sherrit lol
Posted by SherriT on :
Hey, I'm human ;-) This thing hits $25 anytime this year and I will dumbfounded. Although, with FDA approval and strong sales, I supposed anything is possible. DNDN did make a huge run to the $18s from here....
Posted by 10of13 on :
LMAO...sherri...$25 would have been great...but .25 is pretty darn good also...!!!
Posted by scottfest on :
quote:Originally posted by SherriT:
quote:Originally posted by scottfest:
quote:Originally posted by SherriT: Over 4.50 now.....25 in a short time....
Are you saying this thing hits $25? If so, are you thinking this year?
WHOA - no, not at all....I was saying .25 cents had been added in a short period of time. Guess I should have added a space in between my ...
Sorry!
Ahh, just read that wrong lol. I made an all to rare good good move this morning by dumping more money in this thing, keep it coming ENCY.
Posted by netguy81 on :
nice ... way to go .. ENCY * $4.61 !!! I got into ENCY around $3.6 before the canadian approval and i also its $5.00 Call Option ... its a gamble and if this thing gets approved before june 15'th ... the shares are going to soar and so is the value of my options !!
Lets hope FDA approves it !!
Posted by ityab0y on :
kickin butt today. 4.93 aheeeet.
Posted by netguy81 on :
helll yeah .... my shares and options have increased .....
Posted by netguy81 on :
so wats the reason for the increase today ... has the approval already happened and the news leaked out or people are just late to the party !!! Posted by SherriT on :
I think it is going to increase some just on momo leading up to the questionable approval, but I am surprised at this jump today. The Canadian approval didn't even get it above 4.25 except briefly after hours (and then it gapped down the following morning)
I think someone knows something.
Posted by netguy81 on :
i'm quite surprised too .... after the canadian approval, the shares jumped in the after hours and i was hoping to see $5.00 the next day but they gaped down the next day ... tht's why i'm just wondering wats happening here ...
hopefully the shares will not crash in the next cpl of days because of profit taking !!
Posted by SherriT on :
quote:Originally posted by netguy81: i'm quite surprised too .... after the canadian approval, the shares jumped in the after hours and i was hoping to see $5.00 the next day but they gaped down the next day ... tht's why i'm just wondering wats happening here ...
hopefully the shares will not crash in the next cpl of days because of profit taking !!
Exactly.
Posted by scottfest on :
Wow! What a way to start the day. Let's hope it stays strong.
Posted by SherriT on :
Back over $5 - let's see how far she can go once she REALLY gets past it.....
Posted by stocktrader2006 on :
Holy shnit!!!!!!!!!!!!.......did you just see that?
WTF???
Posted by stocktrader2006 on :
Them dirty b*st*rd MM's just took out a chit load of stop loss orders.
Geeesh! What a bunch a freaking crooks!!!!!!!!!!
Posted by stocktrader2006 on :
This stock market is so corrupted with fraud, it's disgusting!
Posted by SherriT on :
Yep - kinda wishing I had flipped from this morning....
Posted by Schopenhauers Dog on :
So are guys staying in this or not? Is this worth sticking out until the 15th?
Posted by stocktrader2006 on :
I'm Holding - what do I have to lose? Money? lol
Posted by ityab0y on :
Member Rated: posted June 07, 2007 14:04 -------------------------------------------------------------------------------- This stock market is so corrupted with fraud, it's disgusting!
^^ please explain if u can.
Posted by stocktrader2006 on :
quote:Originally posted by ityab0y: Member Rated: posted June 07, 2007 14:04 -------------------------------------------------------------------------------- This stock market is so corrupted with fraud, it's disgusting!
^^ please explain if u can.
Oh, I can, I can indeed.....What, are you going to give me a A,B,C,D, or F grade on my answer? Do your own DD and learn from your own trading experiences.
Posted by ityab0y on :
ur a meanie. F-
Posted by vichingo103 on :
This is crazy!
Posted by netguy81 on :
i'm still staying in this ... i actually made decent money of the June $5.00 Calls ... they got sold because of the stop order i had ... and i went and bought July $10.00 Call .... i'm also holding my shares till 15'th ... !!
Posted by scottfest on :
With all the gain this week everyone should have expected the drop. Take this opportunity to load up again, I am. IMO this thing still has room to grow, especially with approval.
Posted by stocktrader2006 on :
quote:Originally posted by ityab0y: Member Rated: posted June 07, 2007 14:04 -------------------------------------------------------------------------------- This stock market is so corrupted with fraud, it's disgusting!
Make sure you watch Part 1 through 3.
Posted by scottfest on :
Man I'm glad I picked up more on that big drop last week. Go ENCY!
Posted by stocktrader22 on :
$10 soon with FDA approval on the 15th IMO
Posted by scottfest on :
I was thinking towards fall to see $10 but hey, you are much better at this than I am. I would love to see $10 soon.
Posted by stocktrader22 on :
Scotty the FDA approval for Thelin is on the 15th...
Now Thelin is a huge migraine drug that is in over a billion dollar industry.
Gilead has a competing drug, if approved they will share market share, but Thelin is already invading Europe and Canada so it has an edge. Look at the high short position. IF we see approval for Thelin and no approval for Gilead's which is scheduled 3 days later, $15 is not out of the question on a spike.
Posted by scottfest on :
quote:Originally posted by stocktrader22: Scotty the FDA approval for Thelin is on the 15th...
Now Thelin is a huge migraine drug that is in over a billion dollar industry.
Gilead has a competing drug, if approved they will share market share, but Thelin is already invading Europe and Canada so it has an edge. Look at the high short position. IF we see approval for Thelin and no approval for Gilead's which is scheduled 3 days later, $15 is not out of the question on a spike.
True, I keep forgeting about Gilead being so close to the Thelin date. Usually I get out of these pharms the day before FDA decision, but I'm staying in on this one. I have too good of a feeling on this. BTW, that would be awesome of Thelin got approved while Gilead did not, that would certainly spike ENCY again.
Posted by scottfest on :
By the way, I am tempted to buy this stock right up to the 15th. And I may do just that.
Posted by stocktrader22 on :
Just be careful...not approved and this is back to $2
but I love their blood pressure mediciation being developed also.
Posted by scottfest on :
Hope your cruise went well 22.
Posted by Mortimer on :
This thing isn't "anticipating" toward the 15th quite like I had thought. I feel like I'm playing chicken with the FDA.
Be careful all; get your stop losses in order. GTLA.
Posted by stocktrader22 on :
quote:Originally posted by Mortimer: This thing isn't "anticipating" toward the 15th quite like I had thought. I feel like I'm playing chicken with the FDA.
Be careful all; get your stop losses in order. GTLA.
A move from $3.28 to $4.65 isnt anticipating? Yeah it is anticipating, and when Thelin gets approved and shorts burn (IMO of course) this wll be a nice winner. Stop losses wotn do anything, Thelin gets rejected and this gaps down big time
Posted by Stock_Pupil on :
This article's making me 2nd guess this play even if they do get approved if Gilead gets approved their drug is believed to be better.
quote:Originally posted by Stock_Pupil: This article's making me 2nd guess this play even if they do get approved if Gilead gets approved their drug is believed to be better.
So sell... Even if Gilead drug gets approved it doesnt matter, ENCY has a large market share and head start in Europe and Canada, and they will split market share with Gilead in the US. the market already knows all of this. Without Gilead competition ency on approval could have been $12-$15 now i believe it will be $8+ instead.
Posted by stocktrader2006 on :
No guts, no glory.
Posted by scottfest on :
quote:Originally posted by Stock_Pupil: This article's making me 2nd guess this play even if they do get approved if Gilead gets approved their drug is believed to be better.
You ever notice analyst tell you to buy after it's gone up and tell you to sell after it goes down?
Posted by stocktrader2006 on :
quote:Originally posted by scottfest:
quote:Originally posted by Stock_Pupil: This article's making me 2nd guess this play even if they do get approved if Gilead gets approved their drug is believed to be better.
You ever notice analyst tell you to buy after it's gone up and tell you to sell after it goes down?
Ya, that proves that they short the chit out of it.
Posted by scottfest on :
Damn dirty shorts!
Posted by SherriT on :
Two more days until we get the sealed envelope....
Posted by Stock_Pupil on :
Lesson Learned, thanks for the input.
Posted by scottfest on :
Thanks Adam Feuerstein. The reason this thing hasn't blown up in anticipation is that by comparison, it is a smaller company under the radar. But a couple of messege boards asking why this thing isn't exploding and Adam wants to publish an article without mentioning all of the other successes in the pipeline which make this a solid company. I could probably find a dozen brokers to go the other way. I am in this big, so I believe it will get approved. All of this ranting is of course, just my opinion.
Posted by Mortimer on :
quote:Originally posted by stocktrader2006: This stock market is so corrupted with fraud, it's disgusting!
Looks like another one of those days.
Posted by scottfest on :
Any last predictions on this one before tomorrow?
Posted by vichingo103 on :
im in this big...lets hope..should be approved anyway...
at about what time are we gonna know the decision?
Posted by stocktrader22 on :
Well since ENCY is a big part of my dads portfolio he didnt want to take too big of a chance, an all or nothing deal like I was hoping for. But you can never go wrong with profit. Sold to cover initial capital and a nice profit, and now riding those extra shares for approval tomorrow.
Posted by scottfest on :
Can't say that I blame you. I actually took proffit last week when it spiked. But I left a lot in as well. Well, good luck to all who are in.
Posted by stocktrader22 on :
Im still in just no risk now.
Posted by SherriT on :
No news yet - hoping for good stuff today!
Posted by stocktrader22 on :
news could be afterhours.. Posted by Mortimer on :
Here we go. I may need some Thelin myself before this is over Posted by Bluemound_Freak on :
I am leaving my office for Mobile here in about an hour and I am hoping that the news is good. I get nervous when I am not sitting with my finger on the trigger with an event horizon! GLTUA!
Posted by Stock_Pupil on :
What's the best way to get the news as soon as it's announced?
Posted by scottfest on :
quote:Originally posted by Stock_Pupil: What's the best way to get the news as soon as it's announced?
I use this, it is pretty fast, but they are not always first in approval news.
6/15/2007 17:46:59 ENCY Encysive Pharmaceuticals Inc N T1
Posted by Wildbill on :
AP Blood Pressure Drug Approved Friday June 15, 6:44 pm ET Drug to Treat Rare High Blood Pressure Condition Approved
WASHINGTON (AP) -- Patients who suffer from a rare disease that causes continuous high blood pressure in the arteries of the lungs received a new treatment choice Friday.
The Food and Drug Administration said it approved Letairis to treat pulmonary arterial hypertension. The condition causes continuous high blood pressure in the arteries that carry oxygen-poor blood from the heart to the lungs. As the arteries narrow, the heart must pump harder, which weakens it with time. The disease affects about 100,000 people in the United States.
ADVERTISEMENT The drug, known generically as ambrisentan, is made by Gilead Sciences Inc., based in Foster City, Calif. The company said the drug would be available next week.
The drug comes with strong warnings as it may cause birth defects and shouldn't be used by women who are pregnant or may become pregnant. It also can cause liver damage. Patients taking the once-daily tablets must undergo monthly blood tests to check for injury to the liver, the FDA said.
A second pharmaceutical company, Encysive Pharmaceuticals Inc., was awaiting word on whether its drug to treat the same condition had been approved. The status of that drug, Thelin, or sitaxsentan sodium, wasn't immediately clear Friday. An FDA spokeswoman referred questions on the drug's status to the company. A spokesman said the Houston company had heard nothing.
Other approved medications to treat the condition include Tracleer and Revatio, a lower dose of the same key ingredient in the impotency pill Viagra.
Posted by Livinonklendathu on :
THIS CO. SUX!!!!!!!!!!!!!!!!!!!!!!!!
Posted by stocktrader22 on :
more like the powerhouse big boys always win (gilead) good thing I played this with free shares, I had a feeling lately something behind the scenes wasnt right
Posted by vichingo103 on :
What are u guys gonna do now?
Sell immediately on monday or keep them and hope??
Or what Mr Given has to say in the conference call?
Posted by ityab0y on :
if its in the ****ter monday, i will hold and hope. If I can sell for a small loss i will sell. The thing that bothers me is that they were banking on this drug for cash flow and now they may have to downsize the company. Its also discouraging this is the third rejection from FDA
Posted by stocktrader22 on :
Its over, Gild and Traceler drug will beat ENCY in price for their drug because they have cash. Encysive needed this one. Only hope is a buyout of rights for Thelin. Otherwise Im selling the rest of my free shares.
Posted by scottfest on :
So if you read my previous entries you know that I have always sold my pharms before FDA decisions. I have missed out on money that way, but I never lose money. I really believed ENCY would get approval on this one. Lesson learned, back to my old ways.
Posted by SherriT on :
I really believed they would too....big boys must have financed that rejection.
Posted by Bluemound_Freak on :
Does anybody think that it would be wise to try to buy up some of these cheap shares? I got caught with my hand in the cookie jar and now am stuck with this! I'm thinking of averaging down here!
Posted by scottfest on :
quote:Originally posted by Bluemound_Freak: Does anybody think that it would be wise to try to buy up some of these cheap shares? I got caught with my hand in the cookie jar and now am stuck with this! I'm thinking of averaging down here!
You probably don't want to hear this, but I agree with 22, this thing is done. Time to focus on making that money back somewhere else.
Posted by Mortimer on :
quote:Originally posted by stocktrader22: Its over, Gild and Traceler drug will beat ENCY in price for their drug because they have cash. Encysive needed this one. Only hope is a buyout of rights for Thelin. Otherwise Im selling the rest of my free shares.
Hold that exit door open stock22, I'm right behind you.
Damage, yes. Not so bad though; it could be much worse for me. I fortunately sold a bunch Friday 4.52 because those wild daily swings really gave me bad karma about how this thing was being traded.
Well, good learning experience. I think I'm done with this company though, at least for a long while. I hope you guys made (it) out fairly unscathed.
Posted by SherriT on :
Yeah, I got out this morning - basically broke even because I sold half on the "big" run. Hate I dumped early though, because I could have made a little more change now....but you never really know....could have kept on going.
Posted by mikeo69 on :
UP UP AND AWAY sorry for you who took a loss ! Going to explode on that big of a drop get in on these prices going back to 5 within a month good month holder. Posted by ityab0y on :
quote: UP UP AND AWAY sorry for you who took a loss ! Going to explode on that big of a drop get in on these prices going back to 5 within a month good month holder.
lol, you serious?
Posted by Schopenhauers Dog on :
quote:Originally posted by mikeo69: UP UP AND AWAY sorry for you who took a loss ! Going to explode on that big of a drop get in on these prices going back to 5 within a month good month holder.
![[Wink]](wink.gif)
![[Big Grin]](biggrin.gif)
![[Smile]](smile.gif)
![[Eek!]](eek.gif)
![[Razz]](tongue.gif)
